Core Laboratories N.V. (CLB)

CLB's first-quarter revenues are likely to have declined from the year-ago period's level. However, cost reductions are expected to have provided modest relief.

Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CLB faces declining revenues, weak margins, geopolitical disruptions and inventory issues, with low dividend yield and overvaluation increasing investor caution.

CLB stock is supported by international expansion, proprietary tech and solid cash flow amid competitive pricing, volatile oil prices and geopolitical tensions.

Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock?

Core Laboratories expects Reservoir Description revenues of $82-$85 million and Production Enhancement revenues of $39-$42 million for the first quarter of 2025.

Core Laboratories Inc. (NYSE:CLB ) Q4 2024 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Larry Bruno - Chairman and Chief Executive Officer Gwen Gresham - Senior Vice Presi...

Core Laboratories (CLB) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.19 per share a year ago.

CLB is expected to report higher revenues from the year-ago period's level. However, despite this revenue growth, the company is expected to face increased operating expenses.

Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.